LIZETTE EBOT: Open Payments
NPI 1508448739 · WICHITA FALLS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,557 in 94 payments from 12 companies in 2025. Trend: 2023 $1,553 · 2024 $1,557 · 2025 $1,557
Food & beverage: $1,557
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $347 |
| Otsuka America Pharmaceutical, Inc. | 20 | $343 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $299 |
| Teva Pharmaceuticals USA, Inc. | 12 | $173 |
| Vanda Pharmaceuticals Inc. | 5 | $91 |
| Lundbeck LLC | 3 | $62 |
| Alkermes, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| E.R. Squibb & Sons, L.L.C. | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $37 |
Products named: REXULTI, INGREZZA, CAPLYTA, UZEDY, FANAPT, AUSTEDO XR, ARISTADA, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
